Clinical trial
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
NCT00105313 · MedImmune LLC, Industry · Terminated
Key facts
| NCT number | NCT00105313 |
|---|---|
| Title | Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia |
| Official title | A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Leukemia, Cancer |
| Intervention type | Drug |
| Interventions | MEDI-507 |
| Enrollment | 80 |
| Start date | Feb 1, 2005 |
| First posted | Mar 14, 2005 |
| Last update posted | Jun 14, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: